home / lobbying / lobbying_activities

lobbying_activities: 2684804

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id filing_uuid filing_type registrant_name registrant_id client_name filing_year filing_period issue_code specific_issues government_entities income_amount expense_amount is_no_activity is_termination received_date
2684804 49b4e2c0-f771-4772-8592-809e511d9164 Q3 HECHT LATHAM SPENCER & ASSOCIATES, INC., FORMERLY KNOWN AS HECHT SPENCER & ASSOC 17966 EMERGENT BIOSOLUTIONS 2021 third_quarter DIS Issues related to the development, manufacture, and distribution of coronavirus vaccines; H.R. 706 and S. 166 - Emergency Support for Substance Use Disorders Act - bills authorizing grants to states and community-based entities to address substance use during COVID-19, including Naloxone distribution for opioid overdose; H.R. 2379 - State Opioid Response Grant Authorization Program Act of 2021 - reauthorizes and expands grant programs for State responses to the opioid use disorder crisis; Draft reauthorization of Comprehensive Addiction and Recovery Act (CARA) expanding access to treatments and recovery programs for addiction, including opioid use; S.4231 - Preparing for the Next Pandemic Act (116th Congress) - provisions for vaccines, treatment, and testing capacity, improvements to Strategic National Stockpile, and public private partnerships for public health emergencies; H.R. 4350 - National Defense Authorization Act for Fiscal Year 2022 - provisions related to chemical and biological defense and access to Naloxone; H.R. 4502 - Department of Labor, Health and Human Services, and Education, and related agencies, appropriations Act, 2022 - Title II Department of Health and Human Services - funding for development, acquisition, and stockpiling of medical countermeasures (MCM) for the U.S. Government, substance abuse treatments and State Opioid Response Grants. HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2021-10-18T12:24:38.403000-04:00
Powered by Datasette · Queries took 11.149ms · Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API